MARKET

ILMN

ILMN

Illumina
NASDAQ

Real-time Quotes | Nasdaq Last Sale

398.85
-0.76
-0.19%
After Hours: 398.50 -0.35 -0.09% 19:21 03/05 EST
OPEN
402.24
PREV CLOSE
399.61
HIGH
403.48
LOW
382.41
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
555.77
52 WEEK LOW
196.78
MARKET CAP
58.19B
P/E (TTM)
89.99
1D
5D
1M
3M
1Y
5Y
Next-Generation Sequencing Market Size 2021 With Top Countries Data, Opportunities by Regions, Emerging Downstream Market Analysis, Technological and Market Developments, Revenue, Prominent Players, Tendencies and Forecast to 2026
The Express Wire · 21h ago
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
Zacks · 1d ago
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
Zacks.com · 1d ago
Global Next-generation Sequencing Market Report 2020-2025 - Enhancing Regulatory Framework for Next-generation Sequencing Based Tests for Diagnostics Driving Growth
Dublin, March 05, Mar 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, March 05, 2021 (GLOBE NEWSWIRE) -- The "Global Next-generation Sequencing Market, by...
GlobeNewswire · 1d ago
New Research Report on Gene Expression Market 2021-2025|Says Kenneth Research
Mar 05, 2021 (AmericaNewsHour) -- The global Gene Expression market was valued at USD 3.62 billion in 2016 and is projected to reach USD 8.03 billion by...
AmericaNewsHour · 1d ago
Impact of Existing and Emerging Multiplex Assays Market Trends 2021-2025|Says Kenneth Research
AmericaNewsHour · 1d ago
Nucleic Acid Isolation and Purification Market Value Chain and Forecast 2021-2025|Says Kenneth Research
Mar 05, 2021 (AmericaNewsHour) -- The global Nucleic Acid Isolation and Purification market was valued at USD 2775.59million in 2016 and is projected to...
AmericaNewsHour · 1d ago
High-Resolution Melting Analysis Market Size, Share 2020: Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2025
Mar 05, 2021 (AmericaNewsHour) -- The global High-Resolution Melting Analysis Market was valued at USD 259.32 million in 2016 and is projected to reach USD...
AmericaNewsHour · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ILMN. Analyze the recent business situations of Illumina through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ILMN stock price target is 408.13 with a high estimate of 570.00 and a low estimate of 270.00.
EPS
Institutional Holdings
Institutions: 1.37K
Institutional Holdings: 139.81M
% Owned: 95.83%
Shares Outstanding: 145.90M
TypeInstitutionsShares
Increased
350
10.95M
New
220
657.56K
Decreased
312
12.07M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.35%
Healthcare Equipment & Supplies
+2.13%
Key Executives
Chairman/Director
Jay Flatley
President/Chief Executive Officer/Director
Francis deSouza
Chief Financial Officer/Senior Vice President
Sam Samad
Senior Vice President/General Counsel/Secretary
Charles Dadswell
Senior Vice President
Phillip Febbo
Senior Vice President
Joydeep Goswami
Senior Vice President
Aimee Hoyt
Senior Vice President
Robert Ragusa
Senior Vice President
Mostafa Ronaghi
Senior Vice President
Mark Van Oene
Chief Technology Officer
Alex Aravanis
Lead Director/Independent Director
John Thompson
Independent Director
Frances Arnold
Independent Director
Caroline Dorsa
Independent Director
Robert Epstein
Independent Director
Scott Gottlieb
Independent Director
Gary Guthart
Independent Director
Philip Schiller
Independent Director
Susan Siegel
No Data
About ILMN
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Webull offers kinds of Illumina, Inc. stock information, including NASDAQ:ILMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ILMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ILMN stock methods without spending real money on the virtual paper trading platform.